Reference is made to the stock exchange announcement by Ultimovacs ASA (the “Company”) on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the “Business Combination”) and the fully committed private placement (the “Private Placement” and together with the Business Combination, the “Transactions”).
Please see the attached forms for information on the conditional allocation of shares in the Company to closely related parties of primary insiders in connection with the Transactions. The transactions reported by in the forms are conditional upon approval by an extraordinary general meeting of the Company and the subsequent completion of the Business Combination and the Private Placement.
This information is subject to the disclosure requirements in article 19 of Regulation EU 596/2014 (the “EU Market Abuse Regulation”) and section 5-12 of the Norwegian Securities Trading Act.
Attachment
- 20241217 PDMR attachment
